iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson's Disease
- Written by PR Newswire
WUHAN, China, June 24, 2024 /PRNewswire/ -- On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's Disease. This marks a significant milestone as NouvNeu001 becomes the world's first chemically induced allogeneic cell...
